298 related articles for article (PubMed ID: 9922964)
21. Vancomycin-resistant Enterococcus faecium infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk.
Worth LJ; Thursky KA; Seymour JF; Slavin MA
Eur J Haematol; 2007 Sep; 79(3):226-33. PubMed ID: 17655696
[TBL] [Abstract][Full Text] [Related]
22. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children.
Kaplan SL; Deville JG; Yogev R; Morfin MR; Wu E; Adler S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB;
Pediatr Infect Dis J; 2003 Aug; 22(8):677-86. PubMed ID: 12913766
[TBL] [Abstract][Full Text] [Related]
23. Daptomycin therapy for invasive Gram-positive bacterial infections in children.
Ardura MI; Mejías A; Katz KS; Revell P; McCracken GH; Sánchez PJ
Pediatr Infect Dis J; 2007 Dec; 26(12):1128-32. PubMed ID: 18043450
[TBL] [Abstract][Full Text] [Related]
24. [Bacteremia caused by vancomycin-resistant Enterococcus faecalis. Report of 2 cases].
Ortega L; Lite J; Garau J
Enferm Infecc Microbiol Clin; 1991 Nov; 9(9):547-50. PubMed ID: 1668361
[TBL] [Abstract][Full Text] [Related]
25. [Emergency of vancomycin-resistant Enterococcus infections in a teaching hospital in Chile].
Fica A; Jemenao MI; Bilbao P; Ruiz G; Sakurada A; Pérez de Arce E; Zúñiga I; Gompertz M
Rev Chilena Infectol; 2007 Dec; 24(6):462-71. PubMed ID: 18180821
[TBL] [Abstract][Full Text] [Related]
26. [Therapeutic impact of streptococcal and enterococcal bacteremia in hematology patients].
Ombandza-Moussa E; Schlegel L; Vekhoff A; Gerbal R; Marie JP; Bouvet A
Pathol Biol (Paris); 2002 Apr; 50(3):169-77. PubMed ID: 11980330
[TBL] [Abstract][Full Text] [Related]
27. [Bacteremia caused by Enterococcus gallinarum with a high level of glycopeptide resistance: 1st documented cases in Argentina].
Togneri A; Lopardo H; Corso A
Rev Argent Microbiol; 2003; 35(2):96-9. PubMed ID: 12920991
[TBL] [Abstract][Full Text] [Related]
28. Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients.
Gallagher JC; Perez ME; Marino EA; LoCastro LG; Abrardo LA; MacDougall C
Pharmacotherapy; 2009 Jul; 29(7):792-9. PubMed ID: 19558253
[TBL] [Abstract][Full Text] [Related]
29. Vancomycin-resistant enterococci bacteremia: risk factors for mortality and influence of antimicrobial therapy on clinical outcome.
Han SH; Chin BS; Lee HS; Jeong SJ; Choi HK; Kim CO; Yong D; Choi JY; Song YG; Lee K; Kim JM
J Infect; 2009 Mar; 58(3):182-90. PubMed ID: 19233476
[TBL] [Abstract][Full Text] [Related]
30. Outcomes for and risk factors associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant Enterococcus faecium bacteremia in cancer patients.
Ghanem G; Hachem R; Jiang Y; Chemaly RF; Raad I
Infect Control Hosp Epidemiol; 2007 Sep; 28(9):1054-9. PubMed ID: 17932826
[TBL] [Abstract][Full Text] [Related]
31. Risk factors for enterococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients.
Mikulska M; Del Bono V; Prinapori R; Boni L; Raiola AM; Gualandi F; Van Lint MT; Dominietto A; Lamparelli T; Cappellano P; Bacigalupo A; Viscoli C
Transpl Infect Dis; 2010 Dec; 12(6):505-12. PubMed ID: 20636482
[TBL] [Abstract][Full Text] [Related]
32. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains.
Jones RN
Clin Infect Dis; 2006 Jan; 42 Suppl 1():S13-24. PubMed ID: 16323115
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer.
Jaksic B; Martinelli G; Perez-Oteyza J; Hartman CS; Leonard LB; Tack KJ
Clin Infect Dis; 2006 Mar; 42(5):597-607. PubMed ID: 16447103
[TBL] [Abstract][Full Text] [Related]
34. Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with synercid (quinupristin/dalfopristin).
McNeil SA; Clark NM; Chandrasekar PH; Kauffman CA
Clin Infect Dis; 2000 Feb; 30(2):403-4. PubMed ID: 10671355
[No Abstract] [Full Text] [Related]
35. Clinical features of enterococcal bacteremia due to ampicillin-susceptible and ampicillin-resistant enterococci: An eight-year retrospective comparison study.
Hamada Y; Magarifuchi H; Oho M; Kusaba K; Nagasawa Z; Fukuoka M; Yamakuchi H; Urakami T; Aoki Y
J Infect Chemother; 2015 Jul; 21(7):527-30. PubMed ID: 25935477
[TBL] [Abstract][Full Text] [Related]
36. Colonization and infection with vancomycin-resistant Enterococcus among patients with cancer.
Matar MJ; Tarrand J; Raad I; Rolston KV
Am J Infect Control; 2006 Oct; 34(8):534-6. PubMed ID: 17015161
[TBL] [Abstract][Full Text] [Related]
37. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia.
Erlandson KM; Sun J; Iwen PC; Rupp ME
Clin Infect Dis; 2008 Jan; 46(1):30-6. PubMed ID: 18171210
[TBL] [Abstract][Full Text] [Related]
38. [Enterococcal infections. Clinical findings and treatment considering antibiotic resistance in Denmark].
Olesen HV; Møller JK
Ugeskr Laeger; 2002 Apr; 164(18):2386-90. PubMed ID: 12024841
[TBL] [Abstract][Full Text] [Related]
39. First recurrent infection with vancomycin-resistant enterococcus from Turkey.
Citak EC; Oguz A; Karadeniz C; Okur V; Basustaoglu A; Arman D
J Infect; 2006 Sep; 53(3):e147-50. PubMed ID: 16413059
[TBL] [Abstract][Full Text] [Related]
40. Is vancomycin resistance in enterococci predictive of inferior outcome of enterococcal bacteremia?
Krcmery V; Bilíková E; Svetlansky I; Kovacicová G
Clin Infect Dis; 2001 Apr; 32(7):1110-2. PubMed ID: 11264043
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
